Skip to main content
. 2021 Jul 29;23(10):1662–1672. doi: 10.1002/ejhf.2308

Figure 2.

EJHF-2308-FIG-0002-c

Change in weight over time by body mass index (BMI) category. Change in weight in patients randomized to dapagliflozin and placebo over time within each BMI category demonstrates modest weight loss regardless of baseline BMI in patients randomized to dapagliflozin. There was no significant interaction between baseline BMI and randomized treatment on change in weight.